Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution
Authors:
- 11 February 2022
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 55 (11) , 1163-1168
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Anticancer Agent Shikonin Is an Incompetent Inducer of Cancer Drug ResistancePLOS ONE, 2013
- Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis—radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinibBioorganic & Medicinal Chemistry Letters, 2012
- 99mTc–meropenem as a potential SPECT imaging probe for tumor hypoxiaJournal of Radioanalytical and Nuclear Chemistry, 2011
- Shikonin Derivatives Protect Immune Organs from Damage and Promote Immune Responses In Vivo in Tumour‐bearing MicePhytotherapy Research, 2011
- Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2Oncogene, 2011
- Preparation of 125I-celecoxib with high purity as a possible tumor agentJournal of Radioanalytical and Nuclear Chemistry, 2010
- Synthesis and biological evaluation of 99mTc-DHPM complex: a potential new radiopharmaceutical for lung imaging studiesJournal of Radioanalytical and Nuclear Chemistry, 2009
- Kinetics and reactivities of ruthenium(III)- and osmium(VIII)-catalyzed oxidation of ornidazole with chloramine-T in acid and alkaline media: A mechanistic approachJournal of Molecular Catalysis A: Chemical, 2009
- Evaluation of 99mTc(CO)5I as a potential lung perfusion agentNuclear Medicine and Biology, 2009
- Toward theragnosticsCritical Care Medicine, 2009